20 October 2025
Johnson & Johnson's INLEXZO™ and Cetrelimab Show Promising Pre-Surgical Results in Bladder Cancer
Phase 2b study shows INLEXZO™ plus cetrelimab achieves significant pathologic response rates in muscle invasive bladder cancer patients ineligible for platinum-based chemotherapy.
